CoChat

External Quality Assessment for KRAS Testing Is Needed: Setup of a European Program and Report of the First Joined Regional Quality Assessment Rounds

Open access
Bellon, Ellen, Ligtenberg, Marjolijn J.L., Tejpar, Sabine, Cox, Karen, Hertogh, Gert, Stricker, Karin, Edsjö, Anders, Gorgoulis, Vassilis, Höfler, Gerald, Jung, Andreas, Kotsinas, Athanassios, Laurent-Puig, Pierre, López-Ríos, Fernando, Hansen, Tine Plato, Rouleau, Etienne, Vandenberghe, Peter, Krieken, Johan J.M., Dequeker, Elisabeth · 2011 · The Oncologist
Cited by 83

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Learning Objectives: After completing this course, the reader will be able to: Identify the most frequent errors made in KRAS testing in this study and the possible consequences for a patient.Describe factors that could increase the chance of an error during KRAS testing. This article is available for continuing medical education credit at CME.TheOncologist.com The use of epidermal growth factor receptor–targeting antibodies in metastatic colorectal cancer has been restricted to patients with wild-type KRAS tumors by the European Medicines Agency since 2008, based on data showing a lack of efficacy and potential harm in patients with mutant KRAS tumors. In an effort to ensure optimal, uniform, and reliable community-based KRAS testing throughout Europe, a KRAS external quality assessment (EQA) scheme was set up. The first large assessment round included 59 laboratories from eight different European countries. For each country, one regional scheme organizer prepared and distributed the samples for the participants of their own country. The samples included unstained sections of 10 invasive colorectal carcinomas with known KRAS mutation status. The samples were centrally validated by one of two reference laboratories. The laboratories were allowed to use their own preferred method for histological evaluation, DNA isolation, and mutation analysis. In this study, we analyze the setup of the KRAS scheme. We analyzed the advantages and disadvantages of the regional scheme organization by analyzing the outcome of genotyping results, analysis of tumor percentage, and written reports. We conclude that only 70% of laboratories correctly identified the KRAS mutational status in all samples. Both the false-positive and false-negative results observed negatively affect patient care. Reports of the KRAS test results often lacked essential information. We aim to further expand this program to more laboratories to provide a robust estimate of the quality of KRAS testing in Europe, and provide the basis for remedial measures and harmonization.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2010-0429

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 83

Metadata

Authors
Bellon, E., Ligtenberg, M. J. L., Tejpar, S., Cox, K., Hertogh, G., Stricker, K., Edsjö, A., Gorgoulis, V., Höfler, G., Jung, A., Kotsinas, A., Laurent-Puig, P., López-Ríos, F., Hansen, T. P., Rouleau, E., Vandenberghe, P., Krieken, J. J. M., & Dequeker, E.
Venue
The Oncologist
Published
2011-03-26
Volume
16
Issue
4
Pages
467-478
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W2100008522
Cited by
83
References
5
FWCI
10.40
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.